ACM
BNTX icon

Asymmetry Capital Management’s BioNTech BNTX Stock Holding History

Asymmetry Capital Management’s Portfolio BNTX Stock Details BNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-38,626
Closed -$2.58M – 37
2020
Q2 		$2.58M Buy
+38,626
New +$1.93M 1.98% 19

Other funds holding BNTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Asymmetry Capital Management's BNTX Position: Q3 2020 in Review

Asymmetry Capital Management sold out of BioNTech (BNTX) in Q3 2020, closing a stake of 38,626 shares — an estimated $2.58M sold.

Asymmetry Capital Management first reported a position in BNTX in Q2 2020 and held it in 1 quarter. The position peaked at $2.58M in Q2 2020. 147 funds tracked by Wall St. Rank hold BNTX as of Q3 2020.

  • Asymmetry Capital Management reported no remaining BioNTech position as of Q3 2020 after selling out during the quarter.
  • Asymmetry Capital Management sold 38,626 BioNTech shares in Q3 2020, an estimated $2.58M.
  • Asymmetry Capital Management first reported a position in BioNTech in Q2 2020 and held it in 1 quarter.
  • Asymmetry Capital Management's BioNTech position peaked at $2.58M in Q2 2020.
  • 147 funds tracked by Wall St. Rank held BioNTech as of Q3 2020.

Based on Asymmetry Capital Management's 13F filing for Q3 2020, filed 12 Nov 2020.